Author/Authors :
Sarafnejad, Abdolfattah Department of Immunology - School of Public Health - Tehran University of Medical Sciences, Tehran , Khosravi, Farideh Department of Immunology - Medical School - Tehran University of Medical Sciences, Tehran , Alimoghadam, Kamran Department of Hematology - Oncology and BMT - Shariati Hospital - Tehran University of Medical Sciences, Tehran , Dianat, Saied Department of Immunology - Medical School - Tehran University of Medical Sciences, Tehran , Ansaripour, Bita Department of Immunology - Medical School - Tehran University of Medical Sciences, Tehran , Moradi, Batoul Department of Immunology - Medical School - Tehran University of Medical Sciences, Tehran , Dorkhosh, Shahin Department of Immunology - Medical School - Tehran University of Medical Sciences, Tehran , Amirzargar, Aliakbar Department of Immunology - Medical School - Tehran University of Medical Sciences, Tehran
Abstract :
Previous studies have demonstrated some significant differences in HLA allele
frequencies in leukemic patients and normal subjects.
We have analyzed HLA class II alleles and haplotypes in 60 Iranian patients with acute
myelogenous leukemia (AML) and 180 unrelated normal subjects. Blood samples were
collected after obtaining informed consents. From the patients and control DNA extraction
and HLA typing were performed using PCR-SSP method.
Significant positive association with the disease was found for HLA-DRB1*11 allele (35%
vs. 24.7%, p=0.033). Two alleles including HLA-DRB4 and –DQB1*0303 were found to be
significantly decreased in patients compared to controls. Regarding haplotype analysis, no
significant association was found between case and control groups.
It is suggested that HLA-DRB1*11 allele plays as a presumptive predisposing factor while
the HLA-DRB4 and –DQB1*0303 alleles are suggested as protective genetic factors against
acute myelogenous leukemia. Larger studies are needed to confirm and establish the role of
these associations with acute myelogenous leukemia.
